Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2018

01-06-2018 | Endocrine Imaging

Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma

Authors: V. Del Gatto, C. Bima, S. Chiloiro, A. Giampietro, A. Bianchi

Published in: Endocrine | Issue 3/2018

Login to get access

Excerpt

Prolactinomas represent 40% of pituitary tumors and are typically benign. According to WHO Classification of Tumours of Endocrine Organs, aggressive prolactinomas occur more frequently in males, as giant and invasive lesions with increased risk of recurrence and resistance to medical treatment [1]. …
Literature
1.
R.V. Lloyd, R.Y. Osamura, G. Kloppel, J. Rosai, WHO Classification of Tumors of Endocrine Organs (WHO International Agency, Lion France, 2017)
2.
A. Fusco, F. Lugli, E. Sacco, L. Tilaro, A. Bianchi, F. Angelini, A. Tofani, A. Barini, L. Lauriola, G. Maira, A. Pontecorvi, L. De Marinis, Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary 14, 351–357 (2011). https://​doi.​org/​10.​1007/​s11102-008-0162-y CrossRefPubMed
3.
Metadata
Title
Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma
Authors
V. Del Gatto
C. Bima
S. Chiloiro
A. Giampietro
A. Bianchi
Publication date
01-06-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1486-z

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue

Research Letter

Bone safety of dual-release hydrocortisone in patients with hypopituitarism

Original Article

Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer

Original Article

The effects of Exendin-4 on bone marrow-derived mesenchymal cells

Letter to the Editor

Impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on the risk of malignancy estimated by the ultrasonographic classification of the American Thyroid Association (ATA) in thyroid nodules >1 cm

Original Article

Sexual function and sex hormones in breast cancer patients

Original Article

Higher free triiodothyronine concentration is associated with lower prevalence of microangiopathic complications and better metabolic control in adult euthyroid people with type 1 diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits